Abstract 125P
Background
Immunotherapy is vital for melanoma treatment, with tumor vaccines showing promise. Previous studies suggest circadian rhythms may impact immune responses, yet their effect on tumor vaccine efficacy is unclear. To optimize vaccine outcomes, we investigated the differences in melanoma treatment efficacy when vaccines were administered at different times, aiming to find the optimal therapeutic window.
Methods
We compared the efficacy of a neoantigen tumor vaccine developed by our team when administered during the active phase (ZT21) versus the rest phase (ZT9) in C57BL/6 mice with B16-F10 melanoma (ZT refers to Zeitgeber Time, where ZT0 is the time of lights on, and ZT12 is lights off). IVIS imaging was used to track vaccine targeting of lymph nodes at different time points. Flow cytometry, immunohistochemistry, and RT-PCR were performed to assess changes in CD8+ and CD4+ T cells in the tumor microenvironment, lymph nodes, and spleen post-vaccination.
Results
In a melanoma model, vaccine administration during the rest phase (ZT9) showed better tumor inhibition compared to the active phase (ZT21). IVIS results indicated faster lymph node targeting at ZT9. Flow cytometry and immunohistochemistry revealed that ZT9 administration increased tumor-infiltrating CD8+ and CD4+ T cells, with a higher proportion of CD69+ T cells, leading to stronger anti-tumor immune responses.
Conclusions
Administering tumor vaccines during the rest phase, compared to the active phase, leads to faster lymph node targeting and stronger anti-tumor immune responses, resulting in better therapeutic outcomes. Thus, treatment timing should be considered in clinical immunotherapy, with vaccines administered during the rest phase for maximum clinical benefit.
Legal entity responsible for the study
West China Hospital, Sichuan University.
Funding
Sichuan Science and Technology Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - Anti-CTLA4 therapy leads to early expansion of peripheral Th17 population and induction of Th1 cytokines
Presenter: Mari Nakazawa
Session: Poster Display session
Resources:
Abstract
196P - Single-cell analysis of stage-I high-grade serous ovarian carcinoma reveals the essential role of regulatory T cells in early tumor establishment
Presenter: Joanna Mikulak
Session: Poster Display session
Resources:
Abstract
197P - Comprehensive immunoprofiling of the intratumoral and peripheral T cell receptor gene repertoire in triple-negative breast cancer patients
Presenter: Antonios Mingos
Session: Poster Display session
Resources:
Abstract
198P - Association of types of treatment modalities with expression of T Lymphocytes (CD4, CD8, Treg) in breast cancer patients and their clinical outcome
Presenter: Arshi Rizwan
Session: Poster Display session
Resources:
Abstract
199P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Poster Display session
Resources:
Abstract
200P - CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant NSCLC
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
201P - Underlying mechanisms of neutrophil-mediated immunosuppression and resistance to treatment in breast cancer: Further evidence that these cells matter
Presenter: Bruna Filipa Correia
Session: Poster Display session
Resources:
Abstract
202P - Mining tumor infiltrating B cells to discover antibody-target pairs and develop novel therapies
Presenter: Matthieu Delince
Session: Poster Display session
Resources:
Abstract
203P - Targeting IL-33 reprograms tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
Presenter: Xuyao Zhang
Session: Poster Display session
Resources:
Abstract
204P - Deciphering the crosstalk between tumor and circulating immune microenvironment in advanced NSCLC patients undergoing immunotherapy
Presenter: Prisca Tamarozzi
Session: Poster Display session
Resources:
Abstract